I-131-Apamistamab | m-entrepreneurship.com

Product Name :
I-131-Apamistamab

Search keywords :
LY5

drugId :
null

Target Vo:
Leukocyte common antigen

Target Vo Short Name :
L-CA

Moa_Name:
Anti-CD45

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Fred Hutchinson Cancer Research Center

Active Company_Name :
Actinium Pharmaceuticals Inc

Active Indication_Name:
Leukemia, Myeloid, Acute

In Active Indication_Name:
Burkitt Lymphoma

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Prasinezumab Epigenetic Reader Domain
L-α-lysophosphatidylinositol (Soy) Technical Information
CD163 Antibody: CD163 Antibody is an unconjugated, approximately 130 kDa, rabbit-derived, anti-CD163 polyclonal antibody. CD163 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, and predicted: rat, dog, pig, horse background without labeling.

Author: Betaine hydrochloride

Related Posts